Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.51 |
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.50 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14365336 | 0.77 | HTR6 (0.58) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL29429815 | 0.74 | HTR6 (0.56) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL6039811 | 0.74 | HTR6 (0.56) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL15648458 | 0.73 | HTR6 (0.55) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL19054640 | 0.73 | HTR6 (0.58) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL724278 | 0.72 | HTR6 (0.61) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL29728507 | 0.72 | HTR6 (0.61) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL19054622 | 0.72 | HTR6 (0.53) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL1724114 | 0.72 | CCNK (0.56) | CCNKCDK12CDK8JAK1 | |
| SCHEMBL28862174 | 0.70 | HTR6 (0.53) | HTR6DRD2HTR2AHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | HTR6 3963/4885DRD2 4378/4885HTR2A 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.